Tag: MP1032

MetrioPharm Announces Topline Data of its Phase IIa Study of MP1032 in COVID-19 Patients

— Orally administered MP1032 with very favorable safety and tolerability profile

— Compound equally effective as Remdesivir or Nirmatrelvir/Ritonavir as monotherapy

— Oral administration and suitability for early intervention address high unmet medical need

MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory diseases, today announced topline data of its CT05 Phase IIa double-blind placebo-controlled study of small molecule macrophage metabolic modulator MP1032 in COVID-19 patients.

Read more…